Editorial

Immune Regulatory Cells in Inflammation, Infection, Tumor, Metabolism, and Other Diseases 2019

Qingdong Guan ^{1,2,3,4} **Cheng Xiao** ⁵ and **Minggang Zhang**⁶

¹Cellular Therapy Laboratory, Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Winnipeg, Canada

²Department of Internal Medicine, University of Manitoba, Winnipeg, Canada

³Department of Immunology, University of Manitoba, Winnipeg, Canada

⁴Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada

⁵Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China

⁶Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, USA

Correspondence should be addressed to Qingdong Guan; qguan@hsc.mb.ca

Received 11 September 2019; Accepted 12 September 2019; Published 23 October 2019

Copyright © 2019 Qingdong Guan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The immune regulatory components of the immune system, such as immune regulatory cells and regulatory cytokines, either natural or induced, play important roles in controlling a variety of physiological and pathological immune responses [1]. In the past years, great advances have been made in studying the physiopathological and therapeutic roles of immune regulator cells in inflammation, infection, tumor, transplantation, autoimmune diseases, and other diseases, such as mesenchymal stromal/stem cells (MSC) and regulatory T cells. MSC are being tested widely as a cellular therapy for autoimmune diseases and other diseases through modulating immune responses and/or promoting tissue repair [2–4]. Through proteomic analysis, we developed a reliable, rapid, and relevant potency assay for clinical grade MSC which is correlated with immunological function of MSC, and this may enhance the standardization of MSC cell products and ultimately promote the development of new MSC treatments [5, 6].

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells that are imbalanced during cancer, transplantation, allergy, and other diseases and have a remarkable ability to suppress various T cell responses and to promote regulatory T cell expansion through multiple mechanisms [7–10]. The adoptive transfer of MDSCs sorted from animal models or generated in vitro could improve transplantation and autoimmune diseases, while targeting MDSC can improve cancer treatment. In this special issue, H. Ma and C.-Q. Xia summarized the phenotype

and functional characteristics of MDSC and reviewed recent advances on their roles in the pathogenesis of autoimmune diseases and potential therapeutic applications.

Dendritic cells and macrophages are professional antigen-presenting cells with the ability to suppress or instigate immune responses and to bridge innate and adaptive immunity. In this issue, M. Mraz et al. evaluated the presence of HLA-DR⁺lineage[−] DC and their subtype in peripheral blood and subcutaneous and epicardial adipose tissue in subjects with T2DM and with T2DM undergoing elective cardiac surgery and showed that T2DM decreased the amount of total DC but increased plasmacytoid DC in subcutaneous adipose tissue. H. Xu et al. showed that IL-10 deficiency restored the type 1 immune response through DC activation, thus providing better protection against TB infection. Using marrow cells from male FVB/N (control) and transgenic hypertensive animals, cells treated with M-CSF and subsequently with LPS and IFN- γ polarized into M1 macrophages and with IL-4 and IL-13 treatment cells polarized to M2 phenotype. P. A. M. Cavalcante et al. compared stimulated macrophages in vitro and found that cells from hypertensive mice were predisposed toward polarization to an M2 phenotype.

Proinflammatory cytokines and regulatory cytokines also play important roles in the physiopathology of diseases. In this special issue, E. Grudzinska et al. evaluated the levels of chemokines and growth factors produced by lymphocytes

in the incompetent great saphenous vein. J. P. T. Guimaraes et al. explored the leukotriene involvement in the insulin receptor pathway and macrophage profiles in muscles from type I diabetic mice and showed that diabetic $5LO^{-/-}$ mice (lack of leukotriene synthesis) had a higher expression of insulin receptor and AKT phosphorylation and increased the expression of anti-inflammatory molecules IL-10, Arg1, and Ym1 and reduced the expression of proinflammatory cytokine IL-6 in muscle macrophage.

In response to IL-17, airway epithelial cells can produce antimicrobial proteins and neutrophil chemoattractants such as CXCR2 ligands. In order to understand how IL-17 exerts downstream effects on its target cells through epigenetic mechanisms, J. Luo et al. showed that IL-17-induced CXCR2 ligand productions are dependent on histone acetylation specifically through repressing HDAC5, and the recognition of acetylated histones plays a pivotal role. However, IL-17 responses were regulated differently by the DNA methylation mechanisms in specific lineages. By focusing on IFN signaling, H. M. Johnson et al. showed that ligand, IFN receptor, the JAKs, and the STATs all undergo endocytosis and ATP-dependent nuclear translocation to promoters of genes specifically activated by IFNs, which indicated that the vacuolar ATPase (V-ATPase) proton pump probably plays a key role in endosomal membrane crossing by IFNs for receptor cytoplasmic binding.

Innate lymphoid cells (ILCs) are a novel family of innate immune cells, which are shown to be critical for integrated mucosal immunity. L. Han et al. summarized studies about ILCs in inflammatory bowel disease (IBD), crosstalk of ILCs with intestinal microbiota, and the relationship of ILCs in enteric nervous system (ENS).

Using a guinea pig model of lipopolysaccharide- (LPS-) induced sudden sensorineural hearing loss (SSHL), L. Xia et al. studied the role of MAP kinase phosphatase-1 (MKP-1) and rosiglitazone (RSG) in glucocorticoid resistance/sensitivity. Severe hearing loss was observed in the LPS group, as opposed to the protection from hearing loss in the treatment of LPS, DEX, and RSG. A positive correlation was found between MKP-1 levels and protection from hearing loss. RSG and DEX synergistically influenced inner ear inflammation may result from impaired MKP-1 function in inner ear tissues, suggesting a novel target to develop potential therapeutics for inflammatory diseases of the inner ear.

Overall, we believe that these articles may improve our knowledge of immune regulatory cell-mediated immune mechanisms in infection, inflammation, tumor, and other diseases, providing insights into designing effective immunodiagnostic and potential therapeutic strategies.

Conflicts of Interest

The authors declare no financial conflict of interest.

Acknowledgments

We would like to thank the authors for their cutting-edge research data and thought-provoking reviews. We also

express our gratitude to all the reviewers for their kind assistance and valuable insights.

Qingdong Guan
Cheng Xiao
Minggang Zhang

References

- [1] Q. Guan, C. Xiao, and M. Zhang, "Immune regulatory cells in inflammation, infection, tumor, metabolism, and other diseases," *Mediators of Inflammation*, vol. 2018, Article ID 4170780, 2 pages, 2018.
- [2] F. van den Akker, S. C. de Jager, and J. P. Sluiter, "Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors," *Mediators of Inflammation*, vol. 2013, 181013 pages, 2013.
- [3] J. Y. Oh, T. W. Kim, H. J. Jeong et al., "Intraperitoneal infusion of mesenchymal stem/stromal cells prevents experimental autoimmune uveitis in mice," *Mediators of Inflammation*, vol. 2014, Article ID 624640, 9 pages, 2014.
- [4] J. Galipeau and L. Sensebe, "Mesenchymal stromal cells: clinical challenges and therapeutic opportunities," *Cell Stem Cell*, vol. 22, no. 6, pp. 824–833, 2018.
- [5] Q. Guan, P. Ezzati, V. Spicer, O. Krokhin, D. Wall, and J. A. Wilkins, "Interferon γ induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells," *Clinical Proteomics*, vol. 14, no. 1, p. 26, 2017.
- [6] Q. Guan, Y. Li, T. Shpiruk, S. Bhagwat, and D. A. Wall, "Inducible indoleamine 2, 3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells," *Cytotherapy*, vol. 20, no. 5, pp. 639–649, 2018.
- [7] D. I. Gabrilovich, "Myeloid-derived suppressor cells," *Cancer Immunology Research*, vol. 5, pp. 3–8, 2017.
- [8] Q. Zhang, M. Fujino, J. Xu, and X. K. Li, "The role and potential therapeutic application of myeloid-derived suppressor cells in allo- and autoimmunity," *Mediators of Inflammation*, vol. 2015, Article ID 421927, 14 pages, 2015.
- [9] Q. Guan, A. R. Blankstein, K. Anjos et al., "Functional myeloid-derived suppressor cell subsets recover rapidly after allogeneic hematopoietic stem/progenitor cell transplantation," *Biology of Blood and Marrow Transplantation*, vol. 21, no. 7, pp. 1205–1214, 2015.
- [10] Q. Guan, B. Yang, R. J. Warrington et al., "Myeloid-derived suppressor cells: roles and relations with Th2, Th17 and Treg cells in asthma," *Allergy*, 2019.